In severe asthma, benralizumab reduced daily oral glucocorticoid dose and asthma exacerbations at 6 months

Resultado de la investigación: Comment/debate › revisión exhaustiva

ASJC Scopus subject areas

@article{1333e71558514fb2a25818985a7a3288,

title = "In severe asthma, benralizumab reduced daily oral glucocorticoid dose and asthma exacerbations at 6 months",

author = "Maselli, {Diego J.} and Peters, {Jay I.}",

year = "2017",

month = oct,

day = "17",

doi = "10.7326/ACPJC-2017-167-8-043",

language = "English (US)",

volume = "167",

pages = "JC43",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "8",

}

TY - JOUR

T1 - In severe asthma, benralizumab reduced daily oral glucocorticoid dose and asthma exacerbations at 6 months

AU - Maselli, Diego J.

AU - Peters, Jay I.

PY - 2017/10/17

Y1 - 2017/10/17

UR - http://www.scopus.com/inward/record.url?scp=85031901159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031901159&partnerID=8YFLogxK

U2 - 10.7326/ACPJC-2017-167-8-043

DO - 10.7326/ACPJC-2017-167-8-043

M3 - Comment/debate

C2 - 29049762

AN - SCOPUS:85031901159

SN - 0003-4819

VL - 167

SP - JC43

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 8

ER -